143 related articles for article (PubMed ID: 14581710)
1. Progress in pharmacotherapy of thrombosis.
Labuzek K; Krysiak R; Okopien B; Herman ZS
Pol J Pharmacol; 2003; 55(4):523-33. PubMed ID: 14581710
[TBL] [Abstract][Full Text] [Related]
2. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
3. [Constitutional thrombopathies: from the clinical description of rare diseases (Glanzmann thrombasthenia and Bernard-Soulier syndrome) to the development of new antithrombotic agents].
Caen J; Bellucci S
Bull Acad Natl Med; 1998; 182(7):1493-502; discussion 1502-3. PubMed ID: 9916343
[TBL] [Abstract][Full Text] [Related]
4. [New anticoagulants].
Levi M; Peters RJ; Piek JJ; Büller HR
Ned Tijdschr Geneeskd; 2003 May; 147(19):909-15. PubMed ID: 12768805
[TBL] [Abstract][Full Text] [Related]
5. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Harrington RA
Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
8. GP IIb/IIIa blockade during peripheral artery interventions.
Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
[TBL] [Abstract][Full Text] [Related]
9. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis in continuous-flow left ventricular assist devices: pathophysiology, prevention, and pharmacologic management.
Jennings DL; Weeks PA
Pharmacotherapy; 2015 Jan; 35(1):79-98. PubMed ID: 25329333
[TBL] [Abstract][Full Text] [Related]
11. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
12. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
Kandzari DE
Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
[TBL] [Abstract][Full Text] [Related]
13. Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.
Moriguchi A; Mihara K; Aoki T; Maeda M; Tojo N; Matsuoka N; Mutoh S
Eur J Pharmacol; 2004 Sep; 498(1-3):179-88. PubMed ID: 15363993
[TBL] [Abstract][Full Text] [Related]
14. [Helping antibodies. Targeted antithrombotic and fibrinolytic therapy].
Schwarz M; Hagemeyer CE; Peter K; Bode C
Hamostaseologie; 2007 Dec; 27(5):360-2. PubMed ID: 18060247
[TBL] [Abstract][Full Text] [Related]
15. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
Mousa SA
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
[TBL] [Abstract][Full Text] [Related]
16. Platelet receptors as therapeutic targets: Past, present and future.
Jamasbi J; Ayabe K; Goto S; Nieswandt B; Peter K; Siess W
Thromb Haemost; 2017 Jun; 117(7):1249-1257. PubMed ID: 28597906
[TBL] [Abstract][Full Text] [Related]
17. [From the physiopathology of thrombosis to therapeutic targets].
Nurden P; Ndoko S; Nurden AT
Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1210-7. PubMed ID: 11794961
[TBL] [Abstract][Full Text] [Related]
18. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
19. Biomechanical thrombosis: the dark side of force and dawn of mechano-medicine.
Chen Y; Ju LA
Stroke Vasc Neurol; 2020 Jun; 5(2):185-197. PubMed ID: 32606086
[TBL] [Abstract][Full Text] [Related]
20. GPIIb/IIIa inhibitor-induced dethrombosis.
Furman MI; Frelinger AL; Michelson AD
J Thromb Thrombolysis; 2004 Aug; 18(1):11-7. PubMed ID: 15744548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
